DYADIC INTERNATIONAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 USD | -5.36% |
|
-13.35% | -1.24% |
| Mar. 28 | Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 28 | Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 4.2M | Sales 2025 * | 6.1M | Capitalization | 46.07M |
|---|---|---|---|---|---|
| Net income 2024 * | -22M | Net income 2025 * | -31M | EV / Sales 2024 * | 11 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.55 x |
| P/E ratio 2024 * |
-2.41
x | P/E ratio 2025 * |
-1.77
x | Employees | 7 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dyadic International, Inc.
More recommendations
More press releases
| 1 day | -5.36% | ||
| 1 week | -13.35% | ||
| Current month | -4.79% | ||
| 1 month | +0.63% | ||
| 3 months | +2.58% | ||
| 6 months | -11.17% | ||
| Current year | -1.24% |
1 week
1.56
1.84
1 month
1.501.94
Current year
1.191.94
1 year
1.192.40
3 years
1.126.89
5 years
1.1210.98
10 years
0.8010.98
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 16-05-31 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 21-11-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Jack Kaye
BRD | Director/Board Member | 80 | 15-04-30 |
Michael Tarnok
BRD | Director/Board Member | 69 | 14-06-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.59 | -5.36% | 36,590 |
| 24-04-17 | 1.68 | -6.67% | 16,514 |
| 24-04-16 | 1.8 | +7.78% | 5,510 |
| 24-04-15 | 1.67 | -5.11% | 26,231 |
| 24-04-12 | 1.76 | -4.09% | 21,447 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.59
USD
Average target price
7.5
USD
Spread / Average Target
+371.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.24% | 46.07M | |
| -1.82% | 41.35B | |
| +42.21% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- DYAI Stock
